FCRL1 promotes tonic PI3K/AKT signaling and constrains inducible BCR pathways 2260146
The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)
DOI: 10.1093/jimmun/vkag141.867 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Randall Davis und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Fc receptor-like 1 (FCRL1) is an understudied B cell immunoregulatory protein with tyrosine-based signaling in humans and mice that peaks on naïve and memory subsets. Among malignancies, FCRL1 is upregulated by chronic lymphocytic leukemia (CLL) and germinal center (GC)-derived B cell lymphomas that rely on tonic PI3K/AKT signals. Early studies found FCRL1 could co-activate B cell receptor (BCR) functions, but broader understanding of its regulatory roles in human B cells remains limited.
Methods
To interrogate its biology, we used a CRISPR/Cas9 strategy to target FCRL1 in a GC-derived B cell lymphoma cell line that highly expresses it. Single-cell sorting was performed to isolate and expand FCRL1-deficient clones. Indel profiling, mRNA quantification, and flow cytometry analyses confirmed FCRL1 knockout at both the transcript and protein levels. To comprehensively define FCRL1-dependent pathways in an unbiased manner, RNA sequencing (RNA-seq) and gene set enrichment analysis (GSEA) were used to compare FCRL1-sufficient and -deficient cells. Transcriptomic findings were validated by Western blot and phospho-flow cytometry under basal conditions and following BCR stimulation.
Results
Expanded FCRL1-deficient clones showed altered granularity and enhanced BCR-mediated apoptosis. RNA-seq and gene set enrichment analysis (GSEA) revealed that the loss of FCRL1 drove the upregulation of multiple hallmark pathways including mTORC1, NF-kB, apoptosis, INFg, and hypoxia, indicating a repressive role for it in resting B cells. Cells lacking FCRL1 also exhibited reduced global tyrosine phosphorylation (pY) and p-AKT (T308), but had higher Src-family kinase (SFK) and p-PLCg2 activity both at rest and upon BCR ligation.
Conclusion
These results implicate FCRL1 as a dual-regulator, which promotes tonic PI3K/AKT signals but limits inducible BCR activation, and expose its potential significance in B cell-related malignancies and humoral disorders. Funding Source Leukemia Lymphoma Society and the UAB O’Neal Comprehensive Cancer Center Topic Categories Immune Response Regulation: Molecular Mechanisms (IRM)
Zitieren
APA
Davis, R., Huang, J., Honjo, K., Li, R., Tabengwa, E., Feng, H., Leu, C., & Mamidi, M. (2026). FCRL1 promotes tonic PI3K/AKT signaling and constrains inducible BCR pathways 2260146. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.867
Vancouver
Davis R, Huang J, Honjo K, Li R, Tabengwa E, Feng H, et al. FCRL1 promotes tonic PI3K/AKT signaling and constrains inducible BCR pathways 2260146. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.867
BibTeX
@article{Davis2026,
author = {Davis, Randall and Huang, Jifeng and Honjo, Kazuhito and Li, Ran and Tabengwa, Edlue and Feng, Hao and Leu, Chuen-Miin and Mamidi, Murali},
title = {FCRL1 promotes tonic PI3K/AKT signaling and constrains inducible BCR pathways 2260146},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {Supplement_1},
doi = {10.1093/jimmun/vkag141.867}
}
EUVIMED